We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Pre-emptive Abdominal Aortic Aneurysm Sac Embolization During EVAR

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05575570
Recruitment Status : Not yet recruiting
First Posted : October 12, 2022
Last Update Posted : October 12, 2022
Information provided by (Responsible Party):
Stevo Duvnjak, Rigshospitalet, Denmark

Brief Summary:
Pre-emptive abdominal aortic aneurysm sac embolization during endovascular abdominal aortic repair for infrarenal abdominal aortic aneurysm - Randomized study

Condition or disease Intervention/treatment Phase
Abdominal Aortic Aneurysm Without Rupture Device: EVAR Not Applicable

Detailed Description:

In all 100 patients will be included, 50 in each group. i The first group with pre-emptive AAA sac embolization during EVAR and the control group consisted of 50 patients without pre-emptive AAA sac embolization and EVAR.

The primary goal is to investigate if the pre-emptive embolization can reduce the endoleak incidence and AAA shrinkage. Further, to investigate all secondary interventions during the follow-up and any difference between groups and correlation if any with pre-emptive embolization.

Demographic, comorbidities, antiplatelet and anticoagulation drugs, AAA characteristics, patent lumbal and inferior mesenteric artery, intervention characteristics and follow-up data will be recorded and analysed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pre-emptive Abdominal Aortic Aneurysm Sac Embolization During Endovascular Abdominal Aortic Repair for Infrarenal Abdominal Aortic Aneurysm - Randomized Study
Estimated Study Start Date : January 1, 2023
Estimated Primary Completion Date : January 1, 2025
Estimated Study Completion Date : January 1, 2026

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Pre-emptive AAA sac embolization Device: EVAR
EVAR stent graft and embolization material CE marked.

Sham Comparator: No pre-emtive AAA sac embolization Device: EVAR
EVAR stent graft and embolization material CE marked.

Primary Outcome Measures :
  1. Endoleak type 2 incidence, on control CT and ultrasound scanning. Further aneurysm sac regression [ Time Frame: 3 years ]
    Incidence of endoleak type 2 and other endoleak will be noted and analysed. Sac regression comparing the baseline CT aorta scanning and AAA diameter in mm, with control CT or ultrasound scanning.

  2. AAA diameter, measurement on control and/or ultrasound [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Secondary interventions, endovascular secondary interventions( additional embolization, a new stent graft deployment etc) [ Time Frame: 3 years ]
    The type of secondary interventions, incidence, time to secondary intervention, and the outcome will be recorded and analysed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient with 55mm (male) or 50 mm (female) AAA, available for EVAR
  • > 18 year old

Exclusion Criteria:

  • Not accept to participate
  • Ruptured AAA
  • Outside for instruction for the use EVAR
Layout table for additonal information
Responsible Party: Stevo Duvnjak, Principal investigator, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT05575570    
Other Study ID Numbers: H-22000209
First Posted: October 12, 2022    Key Record Dates
Last Update Posted: October 12, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Stevo Duvnjak, Rigshospitalet, Denmark:
sac regression
Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Aneurysm
Aortic Aneurysm, Abdominal
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases
Wounds and Injuries